Screener
Rigel Pharmaceuticals RIGL Payment of cost share to collaboration partner
Discontinued — last reported Q4 '25
Payment of cost share to collaboration partner at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept rigl:PaymentOfCostShareToCollaborationPartner.
The source filing: Rigel Pharmaceuticals’s 10-K, filed March 3, 2026.
- Filed
- Mar 3, 2026, 4:06 PM EST
- Fiscal year
- FY2025
- Accession
- 0001034842-26-000015
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Principal payments of term loans | (7,500) | — | — |
| Net proceeds from issuance of common stock from equity plans | 8,101 | 1,964 | 1,049 |
| Closing purchase price payment related to asset acquisition | — | (10,000) | — |
| Cost share payments to a collaboration partner | — | (3,605) | (2,632) |
| Net cash provided by (used in) financing activities | 601 | (11,641) | 18,367 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (16,109) | 23,960 | 8,327 |
| Cash and cash equivalents at beginning of period | 56,746 | 32,786 | 24,459 |
| Cash, cash equivalents, and restricted cash at end of period | $40,637 | $56,746 | $32,786 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Rigel Pharmaceuticals's payment of cost share to collaboration partner?
- Rigel Pharmaceuticals (RIGL) reported payment of cost share to collaboration partner of $0 in Q4 2025.
- What is the long-term trend for Rigel Pharmaceuticals's payment of cost share to collaboration partner?
- Over 2 years (2022 to 2025), Rigel Pharmaceuticals's payment of cost share to collaboration partner has grown at a -100.0% compound annual growth rate (CAGR), from $15.12M to $0.
- What does payment of cost share to collaboration partner mean?
- Represents cash payments made to collaboration partners to satisfy obligations under joint development or commercialization agreements. This metric highlights the cash impact of shared-cost structures in strategic alliances. It is essential for understanding the net cash burden of maintaining collaborative drug development pipelines.
Ask your AI about Rigel Pharmaceuticals's payment of cost share to collaboration partner.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude